Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis Patients

Figure 1

Ability of baseline sacroiliac joint magnetic resonance imaging (MRI) score (Panel (a)), serum C-reactive protein (CRP) concentration (Panel (b)), and Ankylosing Spondylitis Disease Activity Score (ASDAS) (Panel (c)) to predict at least 20% improvement in the Assessment of Ankylosing Spondylitis International Working Group response criteria (ASAS20) from baseline to week 12, as determined by area under the Receiver Operating Characteristics (ROC) curve. The same analysis results of sacroiliac joint magnetic resonance imaging (MRI) score, serum C-reactive protein (CRP) concentration (Panel (b)), and Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 24 were shown in Panel (d), Panel (e), and Panel (f).

(a) ROC curve result of baseline MRI sacroiliitis score after 12 weeks’ infliximab treatment

(b) ROC curve result of baseline CRP after 12 weeks’ infliximab treatment

(c) ROC curve result of baseline ASDAS score after 12 weeks’ infliximab treatment

(d) ROC curve result of baseline MRI sacroiliitis score after 24 weeks’ infliximab treatment

(e) ROC curve result of baseline CRP after 24 weeks’ infliximab treatment

(f) ROC curve result of baseline ASDAS score after 24 weeks’ infliximab treatment